Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CHMA

Chiasma (CHMA) Stock Price, News & Analysis

Chiasma logo

About Chiasma Stock (NASDAQ:CHMA)

Advanced Chart

Key Stats

Today's Range
$3.76
$3.76
50-Day Range
$3.76
$4.71
52-Week Range
$2.77
$5.74
Volume
147 shs
Average Volume
2.12 million shs
Market Capitalization
$217.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CHMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chiasma and its competitors with MarketBeat's FREE daily newsletter.

CHMA Stock News Headlines

Chiasma Craters on FDA Drug Rejection
The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
MPM ASSET MANAGEMENT LLC Buys - GuruFocus.com
See More Headlines

CHMA Stock Analysis - Frequently Asked Questions

Chiasma, Inc. (NASDAQ:CHMA) issued its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.18. The biotechnology company earned $1.92 million during the quarter, compared to analyst estimates of $1.80 million.

Chiasma (CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Cos (BHC), Meta Platforms (META), GW Pharmaceuticals (GWPH), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
5/06/2021
Today
7/15/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CHMA
CIK
1339469
Fax
N/A
Employees
85
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$74.78 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-113.57%
Return on Assets
-57.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.91
Quick Ratio
7.08

Sales & Book Value

Annual Sales
$1.11 million
Price / Sales
196.11
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.59 per share
Price / Book
2.36

Miscellaneous

Outstanding Shares
57,894,000
Free Float
N/A
Market Cap
$217.68 million
Optionable
Not Optionable
Beta
1.28

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:CHMA) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners